| Order from | U.S. Food and Drug Administration (U.S. FDA) |
|---|
BSE filing, NSE: SYMBIOTEC. Summary written from the filing by ALFA Finder's alert engine.
Symbiotec Pharmalab Ltd: key numbers
- Share price
- ₹1,274.70
- Market cap
- ₹8,191 Cr
- Revenue (annual)
- ₹869.1 Cr
- Net profit (annual)
- ₹109.9 Cr
- Promoter holding
- 33.28%
- FII holding
- 3.79%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Symbiotec Pharmalab Ltd
All →Symbiotec Pharmalab Board Meeting Date
Symbiotec Pharmalab schedules a 5 November 2026 board meeting to consider unaudited quarterly and half-year results. No amounts are proposed.
Symbiotec Pharmalab Share Pledge
Promoters of Symbiotec Pharmalab submitted a revised disclosure to update the lender and trustee names for their pledged share encumbrance.
Symbiotec Pharmalab Other Announcement
Symbiotec Pharmalab Ltd submitted its quarterly shareholding pattern for the period ended September 30, 2026, in compliance with Regulation 31 of the SEBI LODR Regulations.
Symbiotec Pharmalab Other Announcement
Symbiotec Pharmalab has filed the routine quarterly certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ending September 30, 2026.
Symbiotec Pharmalab Other Announcement
Designated persons of Symbiotec Pharmalab sold equity shares worth ₹11.94 crore in the open market. This disclosure complies with PIT Regulation 7(2).
- Value
- ₹11.94 Cr
Symbiotec Pharmalab Earnings Call Transcript: Key Takeaways
Symbiotec reported Q1 FY27 Revenue of ₹218 Cr, but underlying PAT remains soft due to heavy pre-operative expense drags from unmonetized new business segments.
- Call
- Guides 20% growth
Other business update announcements
All →OnMobile Global Business Update
OnMobile Global Limited executed a distribution agreement with Savex Technologies Private Limited for its ONMO+ Smart Console in India. The counterparty is unrelated and no shares were issued, so no value is disclosed.
OnEMI Technology Solutions Business Update
OnEMI Technology Solutions (Kissht) disclosed its Key Performance Indicators for the quarter ended 30 September 2026. The KPIs, including those defined in its May 2026 prospectus, are published on the company website.
Hero MotoCorp Business Update
Hero MotoCorp updated its code of practices for fair disclosure of unpublished price-sensitive information, effective 28 October 2026. The revised code governs disclosure, spokespersons and analyst interactions.
Cybele Industries Business Update
Cybele Industries disclosed joint venture discussions with a third party, still at an initial stage. No agreement has been executed and no value is stated.
Dr. Reddy's Laboratories Business Update
Dr Reddy's says USFDA closed its PAI and GMP inspection at Srikakulam FTO-SEZ Process Unit-02 with VAI classification. The outcome is closed with no monetary penalty.
Vascon Engineers Business Update
Vascon Engineers awarded Neobridge Realty LLP a Rs.72 Crore shell and core work contract over 25 months. The contract is excluding GST and is described as ordinary course of business.
- Value
- ₹72.00 Cr
- Execution
- 25 months